|
KMID : 1146120210050010017
|
|
Journal of Mucopolysaccharidosis and Rare Diseases
2021 Volume.5 No. 1 p.17 ~ p.21
|
|
|
Joint Problems in Patients with Mucopolysaccharidosis Type II
|
|
Kim Min-Sun
Kim Ji-Yeon
Noh Eu-Seon
Kim Chi-Woo
Cho Sung-Yoon
Jin Dong-Kyu
|
|
|
Abstract
|
|
|
|
Hunter syndrome or mucopolysaccharidosis type II (MPS-II) (OMIM 309900) is a rare lysosomal storage disorder caused by deficiency in the activity of the enzyme iduronate-2-sulfatase. This enzyme is responsible for the catabolism of the following two different glycosaminoglycans (GAGs): dermatan sulfate and heparan sulfate. The lysosomal accumulation of these GAG molecules results in cell, tissue, and organ dysfunction. Patients can be broadly classified as having one of the following two forms of MPS II: a severe form and an attenuated form. In the severe form of the disease, signs and symptoms (including neurological impairment) develop in early childhood, whereas in the attenuated form, signs and symptoms develop in adolescence or early adulthood, and patients do not experience significant cognitive impairment. The involvement of the skeletal-muscle system is because of essential accumulated GAGs in joints and connective tissue. MPS II has many clinical features and includes two recognized clinical entities (mild and severe) that represent two ends of a wide spectrum of clinical severities. However, enzyme replacement therapy is likely to have only a limited impact on bone and joint disease based on the results of MPS II studies. The aim of this study was to review the involvement of joints in MPS II.
|
|
|
KEYWORD
|
|
|
Hunter syndrome, Lysosomal storage disease, Mucolopysaccharidosis type II, Joint
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|